Within the last year
Within the past 3 years
1 - 4 of 4 articles
Despite the use of recombinant human erythropoietin (rh‐EPO, epoetin) for more than a decade in treating renal anaemia, there is still considerable debate over optimal target haemoglobin (Hb) levels. Current European and North American guidelines that are based on decade‐old trials aim for...
The efficacy and safety of intravenous (i.v.) and subcutaneous recombinant human erythropoietin (rh‐EPO, epoetin) for the treatment of renal anaemia is well established. Subcutaneous administration of epoetin is recommended by current guidelines because it is more flexible and convenient than...
Several studies have compared the efficacy of once‐weekly subcutaneous (s.c.) epoetin treatment with two or three times weekly treatment in renal anaemia. Epoetin administration frequency has attracted a high level of attention in recent years, and numerous small‐scale studies have shown...
Evidence suggests that an individualized and flexible approach may be beneficial to end‐stage renal disease (ESRD) patients. This article discusses this approach in relation to three issues: target haemoglobin (Hb) level, epoetin dosing frequency/administration and patient management/education...
Read and print from thousands of top scholarly journals.
Sign up with Facebook
Sign up with Google
Already have an account? Log in
Save this article to read later. You can see your Read Later on your DeepDyve homepage.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.